

**Retina Update Featuring The 14th Annual J. Arch McNamara, MD Memorial Lecture**

**Saturday, December 14, 2024**

*Wills Eye Auditorium*

**Conference Description:**

[Click Here to Register for the Livestream!](https://attendee.gotowebinar.com/register/6554389364568894550)

With the emergence of new technologies, treatments, and clinical trial results, ophthalmologists need to understand how to incorporate these advances into clinical care. We will discuss latest advances in the management of inherited and acquired ophthalmic diseases and evidence for emerging therapies and screening modalities. Both didactic and case-based educational formats will be utilized to illustrate current trends in the management of complex and routine ophthalmic patients, taking into account diagnostics as well as nonsurgical and surgical treatment.

This conference will focus on the latest advances in the management of complex medical and surgical retina cases. Both didactic and case-based educational formats will be used to highlight current trends in the management of these complex cases. There will also be a focus on complex cases in the various subspecialties of vitreoretinal disease including pediatrics, uveitis, and inherited retinal diseases.

Aaron Nagiel, MD, PhD is an Assistant Professor of Ophthalmology at Children’s Hospital Los Angeles, affiliated with the USC Roski Eye Institute/Keck School of Medicine in Los Angeles, California. As a surgeon specializing in retinal disorders of childhood and adolescence, he complements this clinical expertise with an active laboratory and translational research program. This includes the establishment of a nationally recognized retinal gene therapy program that has performed dozens of gene therapy surgeries, including for clinical trials.

Dr. Nagiel earned his bachelor’s degree from Harvard University summa cum laude, and then underwent combined MD and PhD training at Cornell University and The Rockefeller University in New York City. After an internship at Memorial Sloan-Kettering Cancer Center, Dr. Nagiel completed both ophthalmology residency and vitreoretinal fellowship at the Stein Eye Institute at UCLA.

Dr. Nagiel is a recipient of numerous grants and awards including the Heed Ophthalmic Foundation Fellowship, the Ronald G. Michels Fellowship Foundation Award, Knights Templar Eye Foundation Career Development Award, a National Eye Institute Clinical Scientist Training Grant (K08), and a Research to Prevent Blindness Career Development Award.

[Thank you to our Exhibitors!](https://willseye.cloud-cme.com/assets/willseye/PDF/Exhibitors/20241214%20Exhibitor%20link%20sheet.pdf)

[Alcon](https://www.alcon.com/)
[Abbvie](https://www.abbvie.com/)
[Apellis](https://apellis.com/)
[Astellas](https://www.astellas.com/us/)
[Bausch + Lomb](https://www.bausch.com/)
[Regeneron](https://www.regeneron.com/)

**At the conclusion of the course, participants should be able to:**

1 Speak with patients about the evolving landscape of IRDs and treatments.

2 Collaborate with peers in preparation for gene therapy interventions and genomic analyses.

3 Understand the current advances in the management of proliferative vitreoretinopathy

4 Coordinate management and treatment plans for patients with dislocated intraocular lenses.

**Accreditation Statement:**

The Wills Eye Hospital is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**Credit Statement Designation:**

Wills Eye Hospital designates this Live Activity for a maximum of 4.00 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Disclosure Statement:**

It is the policy of Wills Eye Hospital that the information presented at Wills Eye Hospital's CME activities will be commercially unbiased and based on scientific and clinical evidence. To help participants make judgments about the presence of commercial bias, Wills Eye Hospital provides information that planners and speakers have disclosed about financial relationships they have with commercial entities that produce, market, re-sell, or distribute health care goods or services consumed by, or used on, patients. All relevant financial relationships have been mitigated.

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| Ralph C. Eagle Jr., MD | Other Planning Committee Member | Nothing to disclose - 10/10/2024 |
| Samir N Patel, MD | Planner | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Regeneron (Relationship has ended) - 07/15/2024 |
| Jason Hsu, MD | Faculty | Consulting Fee-Astellas (Relationship has ended)|Consulting Fee-Gyroscope Therapeutics|Grant or research support-Genentech|Grant or research support-Astellas Pharma|Grant or research support-Stealth Biotherapeutics|Grant or research support-Apellis Pharmaceuticals|Grant or research support-Aldeyra Therapeutics (Relationship has ended) - 11/22/2024 |
| Carl D. Regillo, MD | Faculty | Consulting Fee-Allergan|Consulting Fee-Apellis Pharmaceuticals|Consulting Fee-EyePoint Pharmaceuticals|Consulting Fee-Genentech|Consulting Fee-Novartis|Consulting Fee-Ocugen|Consulting Fee-REGENXBIO, Inc.|Consulting Fee-Regeneron|Consulting Fee-Astellas Pharma|Consulting Fee-Ocular Therapeutix|Consulting Fee-Zeiss|Consulting Fee-Aderum Biotechnologies, Inc.|Consulting Fee-Alcon|Consulting Fee-Bausch + Lomb|Consulting Fee-Boehringer Ingelheim - 08/08/2024 |
| Ajay E. Kuriyan, MD | Faculty | Stocks or stock options, excluding diversified mutual funds-Recens medical|Grant or research support-4DMT|Speakers Bureau-Genentech|Speakers Bureau-Astellas Pharma|Consulting Fee-Alimera Sciences (Relationship has ended)|Grant or research support-Alcon|Grant or research support-Aderum Biotechnologies, Inc.|Consulting Fee-Allergan (Relationship has ended)|Consulting Fee-Bausch + Lomb (Relationship has ended)|Consulting Fee-Spark Therapeutics (Relationship has ended)|Consulting Fee-EyePoint Pharmaceuticals (Relationship has ended)|Consulting Fee-Genentech (Relationship has ended)|Grant or research support-Genentech (Relationship has ended)|Consulting Fee-Optos, Inc. (Relationship has ended)|Grant or research support-Annexon - 02/15/2024 |
| Yoshihiro Yonekawa, MD | Planner | Consulting Fee-Alcon (Relationship has ended)|Consulting Fee-Bausch + Lomb (Relationship has ended)|Consulting Fee-Apellis Pharmaceuticals (Relationship has ended)|Consulting Fee-Genentech|Grant or research support-Genentech|Grant or research support-Regeneron|Grant or research support-Ocugen|Grant or research support-Kyowa Kirin - 11/13/2024 |
| Jose Pulido, MD, MS, MPH, MBA | Faculty | Nothing to disclose - 10/15/2024 |
| Joshua H Uhr, MD | Faculty | Public Corp Stock-Apellis Pharmaceuticals|Consulting Fee-Regeneron - 04/09/2024 |
| Rebecca Procopio, MS | Faculty | Nothing to disclose - 10/09/2024 |
| Duo Xu, MD | Faculty | Consulting Fee-Gyroscope Therapeutics|Advisor-Apellis|Consulting Fee-Bausch + Lomb|Consulting Fee-Zeiss|Consulting Fee-REGENXBIO, Inc.|Consulting Fee-Alimera Sciences (Relationship has ended) - 11/25/2024 |
| Anton Orlin, MD | Faculty | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Allergan (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Zeiss (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Genentech (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Apellis Pharmaceuticals (Relationship has ended) - 10/09/2024 |
| Michael Klufas, MD | Faculty | Consulting Fee-REGENXBIO, Inc.|Consulting Fee-Genentech|Consulting Fee-Regeneron|Honoraria-Coherus (Relationship has ended)|Honoraria-Biogen (Relationship has ended)|Consulting Fee-Abbvie|Grant or research support-Bausch + Lomb|Consulting Fee-Dutch Ophthalmic USA|Consulting Fee-Alimera Sciences - 11/29/2024 |
| Jordan Deaner, MD | Faculty | Consulting Fee-EyePoint Pharmaceuticals (Relationship has ended)|Consulting Fee-Alimera Sciences (Relationship has ended)|Consulting Fee-Genentech (Relationship has ended)|Consulting Fee-Bausch + Lomb (Relationship has ended)|Consulting Fee-Regeneron (Relationship has ended) - 09/25/2024 |
| Aaron Nagiel, MD, PhD | Faculty | Consulting Fee-Astellas Pharma (Relationship has ended)|Consulting Fee-Blue Gen|Consulting Fee-Blue Rock|Consulting Fee-Beacon|Consulting Fee-Alia|Consulting Fee-Immuneering (Relationship has ended)|Consulting Fee-Ultragenyx (Relationship has ended)|Consulting Fee-Eyebiotech|Consulting Fee-Johnson & Johnson|Consulting Fee-Novartis|Consulting Fee-Lexitas|Grant or research support-Spark Therapeutics|Grant or research support-Johnson & Johnson|Grant or research support-Atsena - 11/22/2024 |
| Sidra Zafar, MD | Peer Reviewer | Nothing to disclose - 11/23/2024 |
| Flavius Beca, MD | Peer Reviewer | Nothing to disclose - 11/26/2024 |
| Katherine Talcott, MD | Faculty | Consulting Fee-Genentech|Consulting Fee-4DMT|Speakers Bureau-Genentech|Consulting Fee-Alimera Sciences|Consulting Fee-Abbvie|Consulting Fee-Apellis Pharmaceuticals|Consulting Fee-Bausch + Lomb|Consulting Fee-EyePoint Pharmaceuticals|Consulting Fee-Outlook|Speakers Bureau-Astellas Pharma|Consulting Fee-Regeneron|Consulting Fee-Zeiss|Speakers Bureau-Zeiss|Other: Research-Zeiss - 11/26/2024 |

